Analysis of GSK's Seroxat antidepressant finds key data was held back

LONDON, Sept 17 (Reuters) - A medical journal criticised British drugmaker GlaxoSmithKline on Thursday for delaying access to key data from a trial of its antidepressant Seroxat that would have shown earlier that it is neither safe or effective in adolescents.